President & Chief Executive Officer
Gerri Henwood has served as our President, Chief Executive Officer and a director of the Company since November of 2019. From 2008 to December 2020, Ms. Henwood was the President, Chief Executive Officer and a director of Recro Pharma, Inc. (REPH), a company she founded in 2008. From 2006 to 2013, Ms. Henwood served as the President of Malvern Consulting Group, Inc., or MCG, a pharmaceutical incubator and consulting firm. Before founding MCG, Ms. Henwood was the President and Chief Executive Officer of Auxilium Pharmaceuticals, Inc. (formerly AUXL), or Auxilium, a biopharmaceutical company she founded in late 1999. From 1985 to 1999, Ms. Henwood was the founder and Chief Executive Officer of IBAH, Inc., or IBAH, a contract research organization listed on NASDAQ. Ms. Henwood began her career with Smith Kline & French, now part of GlaxoSmithKline plc. She rose through the ranks to be a brand manager, then the head of Regulatory and Medical Affairs for the U.S. business and then to the position of Group Director—Marketing in the International Pharmaceutical Division.
Ms. Henwood previously served on the board of directors of Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, from 2015 until its acquisition by La Jolla Pharmaceutical Company in June 2020. Before that, she served on the board of directors of Alkermes, Inc. and its successor company, Alkermes, plc, a global biopharmaceutical company, from 2003 until March 2015, and on the board of directors of MAP Pharmaceuticals, Inc., a biopharmaceuticals company, from 2004 until its acquisition by Allergan, Inc. in March 2013. Ms. Henwood also served on the compensation committee of the board of directors of Tetraphase Pharmaceuticals, Inc.
Ms. Henwood holds a B.S. in Biology from Neumann University.
Richard S. Casten
Chief Financial Officer
Prior to joining Baudax, Mr. Casten served as Vice President of Finance, Controller and Treasurer at Lupin Pharmaceuticals, Inc. Previous to Lupin, Mr. Casten served in roles of increasing responsibility at Endo International plc, culminating in his role as Senior Director, Financial Planning and Analysis. Prior to Endo, he served in various financial roles at the Campbell Soup Company. Mr. Casten spent the initial ten years of his career in public accounting, with eight years at Ernst & Young LLP, rising to a Senior Manager, Assurance and Advisory Business Services, and at Fishbein & Company as an Assurance Staff Accountant. He holds a Bachelor of Science in Business and Economics, with a major in Accounting, from Lehigh University and a Master’s in Business Administration from the Johnson School at Cornell University. Mr. Casten is a Certified Public Accountant in both Pennsylvania and California and is a member of American and Pennsylvania Institute of Certified Public Accountants.
Chief Commercial Officer
John Harlow is our Chief Commercial Officer and has over 20 years of branded pharmaceutical experience, including commercial leadership roles in marketing, sales and operations. Before his role at Baudax Bio, he served as the Executive Vice President of Commercial at Recro Pharma from February 2018 to November 2019. He joined Recro Pharma as the Vice President of Marketing in October 2016. From 2015 to 2016, Mr. Harlow served as the Vice President & General Manager of the Pain Business Unit for Endo Pharmaceuticals. Before Endo, Mr. Harlow spent over three years at Shionogi in roles of increasing responsibilities including Vice President, Sales and Marketing and Vice President of Sales, Training and Operations. Before joining Shionogi, Mr. Harlow was a Senior Director of Marketing at King Pharmaceuticals where he oversaw the pain portfolio that was ultimately acquired by Pfizer. Mr. Harlow spent over six years with Novartis Pharmaceuticals in sales management and marketing leadership roles in the Neuroscience business unit.
Earlier in his career, Mr. Harlow was an equity research analyst at Merrill Lynch and a sales representative at Janssen Pharmaceuticals - a Johnson and Johnson company. He earned a B.S. in Biology from Lehigh University and an M.B.A. in Pharmaceutical Management & Marketing from The Stillman School of Business at Seton Hall University.
Stewart McCallum, MD
Chief Medical Officer
Stewart McCallum, M.D. serves as our Chief Medical Officer, previously serving as the Recro Pharma, Inc CMO from December 2015 to November 2019. From 2006 to 2015, Dr. McCallum worked at GlaxoSmithKline plc (GSK), a research-based pharmaceutical and healthcare company. While at GSK he served in a range of roles in discovery and development and ultimately as Clinical Director of the Academic and Sirtuin, Discovery Performance Units. During his time at GSK, Dr. McCallum successfully led high profile drug development programs across a wide variety of therapeutic areas including urology, oncology, gastroenterology, dermatology, stem cell therapies, in vitro fertilization and women’s health. While at GSK he was responsible for the planning, design and execution of comprehensive development plans incorporating medical, regulatory and commercial considerations.
From 1998 to 2006, Dr. McCallum served as an Assistant Professor of Urology at Stanford University Medical Center and the VA Palo Alto Health Care System. Dr. McCallum received his M.D. from the University of Toronto and his B.S. in Biochemistry from the University of Western Ontario. He completed his residency in Urology at the University of Toronto and a Clinical Fellowship in Microsurgery and Male Infertility at the Weill Cornell Medical College at New York-Presbyterian Hospital.
Dr. McCallum is a Certified Diplomat of the American Board of Urology; Fellow of the American College of Surgeons, and Fellow of the Royal College of Surgeons Canada.
Senior Vice President, Regulatory & Quality
Diane Myers serves as the Senior Vice President, Regulatory and Quality. Before her role at Baudax Bio, she served as the Senior Vice President, Regulatory and Quality at Recro Pharma from 2008 to November 2019. From 2008 to 2014, Ms. Myers also served as Senior Vice President of Regulatory Affairs and Quality Assurance for MCG, a pharmaceutical incubator and consulting firm. From 2000 to 2008, Ms. Myers served as Vice President of Regulatory Affairs and Quality at Auxilium. In addition, for more than 15 years she held positions of increasing responsibility at GlaxoSmithKline plc in the Quality Control and Quality Assurance groups within the Biopharmaceutical Research and Development Division.
Ms. Myers holds a B.S. in Biology from Neumann University.
Jyrki Mattila, M.D., Ph.D.
Executive Vice President of Business Development
Dr. Mattila serves as our Executive Vice President, Business Development. He was previously the Executive Vice President, Business Development at Recro Pharma from August 2017 to November 2019. Before his time at Recro, Mr. Mattila served as Chief Business Officer at Lipocine Inc., a specialty pharmaceutical company, from 2010 to 2015, Dr. Mattila held executive management positions, serving as Chief Business Officer at iCeutica Inc. and as President and Chief Executive Officer at LZ Therapeutics, Inc. From 2003 to 2010, Dr. Mattila served as Executive Vice President, Business Development, Product Development and Technical Operations, at Auxilium Pharmaceuticals Inc., where he contributed to Auxilium’s growth from a private start-up to a publicly-traded specialty pharmaceutical company. From 1986 to 2003, Dr. Mattila held positions of increasing responsibility at Orion Corporation in business development, R&D and executive general management.
Dr. Mattila served as a Post-Doctoral Research Fellow at the University of Kansas Medical Center and holds an M.B.A. from the Helsinki School of Economics, a Ph.D. from the Department of Pharmacology at the University of Helsinki and an M.D. from the University of Helsinki Medical Schooll.